New program aims to keep mentally ill out of jail
NCT ID NCT07592884
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a special team-based program called R-FACT for people with serious mental illness who are also involved with the criminal justice system. The program provides intensive, community-based support with close coordination between mental health and justice staff. Researchers compared this to standard outpatient care in 40 participants over 24 months, looking at whether it reduced time spent in jail and improved mental health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Rochester Forensic Assertive Community Treatment (R-FACT) model
- What this could lead to
- If successful, this approach could offer a better way to support people with serious mental illness who are involved with the criminal justice system, potentially reducing incarceration and improving community functioning.
- What could go wrong
- This is a small, completed trial with only 40 participants, so results may not apply broadly. The intervention is behavioral and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
Jan 2020
- Finished
-
Apr 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 or older. * DSM-5 diagnosis of a psychotic disorder, including schizophrenia, schizoaffective disorder, bipolar disorder, or major depression with psychotic features. * Adequate command of English to understand study instructions. * Capacity to provide informed consent. * Under community correctional supervision or undergoing prison release planning at the time of enrollment. Exclusion Criteria: * Age under 18. * Lack of a psychotic disorder diagnosis. * Inability to speak English. * Lack of capacity to provide informed consent. * Absence of community correctional supervision or of release planning. * Presence of legal oversight in the community from a source other than probation or community corrections. Examples include having legal oversight from a mental health court, a drug court, or from an assisted outpatient treatment (AOT) program.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five sessions to quiet trauma nightmares in bipolar disorder
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug